Bactolac Pharmaceutical (BTCA) Stock Price, News & Analysis

Company Overview

Bactolac Pharmaceutical, Inc. engages in the research, development and commercialization of vitamins and neutraceuticals. It offers nutritional supplements and shake powders, resveratrol, probiotics, multivitamins, antioxidant products, sports and hormone supplements, and weight loss and detoxification drugs. The company was founded by Pailla Malla Reddy in 1995 and is headquartered in Hauppauge, NY.

Key Stats

• Today's Range: $120,000.00 to $120,000.00
• 50-Day Range: $120,000.00 to $120,000.00
• 52-Week Range: $120,000.00 to $120,000.00
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTCA Stock Analysis - Frequently Asked Questions

How have BTCA shares performed this year?

Bactolac Pharmaceutical's stock was trading at $120,000.00 at the beginning of the year. Since then, BTCA stock has increased by 0.0% and is now trading at $120,000.00.

How do I buy shares of Bactolac Pharmaceutical?

Shares of BTCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bactolac Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bactolac Pharmaceutical investors own include Grayscale Bitcoin Mini Trust ETF (BTC), Ford Motor (F), Meta Platforms (META), Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO) and Berkeley Energia (BKY).

Company Calendar

• Today: 7/12/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drugs, Proprietaries, & Sundries
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BTCA
• CIK: N/A
• Web: www.nnfa.org
• Phone: (631) 951-4908
• Fax: N/A
• Employees: 126
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.01